19 citations
,
July 2022 in “PNAS Nexus” This study identified a shared gene signature in scarring alopecia subtypes, with increased mast cell presence, suggesting similar treatment approaches may be effective across these hair loss disorders.
103 citations
,
January 2009 in “Carbon” This study found that carbon nanotube impurities induced immunological toxicity in mice, whereas purified nanotubes showed good biocompatibility, suggesting high-temperature thermal treatment may improve nanotube biocompatibility.
This study found that γδ T cells play a role in regulating stromal behavior, influencing the composition and vascularity of fibrotic tissues during the foreign body response.
2 citations
,
January 2026 in “Frontiers in Endocrinology” This review discusses the impaired functionality of regulatory T cells in the pancreas during the development of Type 1 diabetes, highlighting their role in disease pathogenesis, potential of Treg-based therapies, and challenges in clinical applications.
6 citations
,
April 2017 in “Experimental dermatology” This study found that B6.CD80CD86−/− mice developed autoimmune-like alopecia with nearly 100% incidence by 40 weeks, making them a promising model for studying human alopecia areata.
January 2026 in “Immune Network” This review discusses the heterogeneity of Tregs in normal and tumor environments, emphasizing the complexity of targeting tumor-resident Tregs while maintaining systemic immune tolerance, but reports no new findings.
53 citations
,
August 2019 in “American journal of human genetics” This study found that FOXN1 haploinsufficiency is a significant genetic factor causing T cell lymphopenia at birth, linked to reduced thymic function in both humans and mice.
66 citations
,
March 2018 in “British journal of dermatology/British journal of dermatology, Supplement” This article reviews the role of perifollicular regulatory T cells in maintaining hair follicle integrity in the context of hidradenitis suppurativa and calls attention to inflammatory mechanisms without reporting new clinical results.
December 2025 in “Babcock University Medical Journal” This study found that in patients with Alopecia Areata, CD27 and IL-35 levels were significantly higher in those with bacterial infections, suggesting they may be useful as immunological biomarkers.
1 citations
,
September 2025 in “Frontiers in Immunology” In this study, researchers using a Treg-specific HuR-deficient mouse model found that the RNA-binding protein HuR is crucial for stabilizing Foxp3 mRNA, affecting Treg function and immune regulation, with HuR disruption leading to impaired Foxp3 expression and potential autoimmune dysfunction.
64 citations
,
July 2016 in “Journal of Immunology” In this study, blocking the CXCR3 receptor in mice prevented the development of alopecia areata by inhibiting the accumulation of specific T cells in the skin, suggesting a potential therapeutic approach for humans.
48 citations
,
January 2024 in “Immune Network” This review highlights recent insights into how IL-15 influences T cell responses and contributes to immunopathogenesis in various diseases, suggesting its crucial role in TCR-independent activation and potential in optimizing therapeutic strategies.
December 2024 in “Clinical Cosmetic and Investigational Dermatology” This study found that AA may have a protective role in the progression of both HBDC and CRC, suggesting potential new research avenues for treatments of these conditions.
January 2024 in “Wiadomości Lekarskie” This study outlines new strategies for overcoming "cold" tumors, which are typically unresponsive to cancer immunotherapy, with approaches like dendritic cell-based treatments and local immune microenvironment modification, bolstered by both preclinical and clinical trial data.
2 citations
,
July 2022 in “Journal of the Endocrine Society” This study identified several rare genetic variants related to insulin resistance in women with PCOS, highlighting the potential for monogenic conditions in patients with extreme or atypical phenotypes.
11 citations
,
July 2014 in “Gene” This study reports a unique case of common variable immunodeficiency with autoimmunity linked to a heterozygous S250C variant in the autoimmune regulator gene, suggesting a potential molecular basis for this combination.
18 citations
,
January 2017 in “Annals of dermatology/Annals of Dermatology” This study found that Th17 lymphocytes may play a more crucial role than cytotoxic T cells in the development of alopecia areata due to their infiltration around the hair bulb/bulge, which exacerbates hair loss as histopathological grade worsens.
4 citations
,
July 2025 in “Frontiers in Immunology” This study explored peripheral blood immune dysregulation in alopecia areata through single-cell analyses, identifying systemic changes linked to disease severity and key signaling roles for monocytes, NK cells, and memory T cells, suggesting potential therapeutic targets.
This study suggests that using cell-free dexamethasone-primed stem cell media may offer a promising alternative treatment for systemic lupus erythematosus, showing immunomodulatory benefits and therapeutic efficacy in reducing various complications.
January 2024 in “bioRxiv (Cold Spring Harbor Laboratory)” In this study, the researchers found that deleting ceramide synthase 4 in the skin's epidermis alters stem cell differentiation, disrupting hair follicle structure and barrier function, potentially leading to immune responses similar to atopic dermatitis.
1 citations
,
May 2026 in “Nature Communications” This study demonstrated that CD19-CAR T cell therapy may promote structural regeneration in the skin of systemic sclerosis patients, as evidenced by histological improvements and fibroblast population changes, suggesting its potential for tissue remodeling in fibrotic diseases.
61 citations
,
September 2010 in “Genomics” This study found distinct gene expression profiles in alopecia areata-affected skin, suggesting T-cell mediated immune responses and unique gene profiles between different stages of the disease.
4 citations
,
June 2025 in “Cell Reports” In this study using the C3H/HeJ mouse model of alopecia areata, researchers found that hyperexpanded CD8+ T cell clones were sufficient to initiate disease, establishing a causal link between T cell clonality and pathogenicity.
46 citations
,
October 2018 in “JCI insight” In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.
6 citations
,
January 2023 in “International journal of molecular sciences” This review discusses the bidirectional interactions between human mast cells and CD8 T cells in the skin, particularly in the context of disorders like psoriasis, atopic dermatitis, and vitiligo, and reports no new findings.
245 citations
,
October 2015 in “Nature medicine” The research found that hair follicle–derived cytokines, particularly IL-15 and IL-7, regulate skin-resident memory T cells and their role in both immune homeostasis and lymphoma in the skin.
3 citations
,
January 2023 in “JEADV Clinical Practice” This study suggests that IL-17 may play a more significant role than IFN-γ in the pathogenesis of chronic alopecia areata, with increasing severity linked to Th17 lymphocytes and cytotoxic T lymphocyte infiltration.
April 2026 in “Frontiers in Medicine” This study found that activating hair follicle resident T cells in a human organ culture can induce an alopecia areata-like immune response, and that the drug farudodstat partially reduced this effect.
May 2023 in “Frontiers in Immunology” This article discusses the role of regulatory T cells in alopecia areata, where their deficiency in hair follicles may lead to impaired local immunity and suggests potential therapies like CAR-T reg cells and low-dose IL-2 to alleviate autoimmunity and promote hair regeneration in affected individuals.
July 2024 in “Journal of Investigative Dermatology” This study found that in mice with alopecia areata, CD8+ T cells showed clonal expansion and specific regulatory networks, which might help identify new therapeutic targets for patients not responding to JAK inhibitors.